Johnson & Johnson (NYSE: JNJ) reported its second quarter 2024 earnings results today. Reported sales increased 4.3% year-over-year to $22.4 billion. Operational sales growth was 6.6%. Net income decreased 12.8% to $4.6 billion while EPS dropped 5.9% to $1.93. Adjusted EPS rose 10.2% to $2.82. Revenue and earnings beat estimates. For the full year of 2024, […]
“Johnson & Johnson (NYSE: JNJ) reported its second quarter 2024 earnings results today. Reported sales increased 4.3% year-over-year to $22.4 billion. Operational sales growth was 6.6%. Net income decreased 12.8% to $4.6 billion while EPS dropped 5.9% to $1.93. Adjusted EPS rose 10.2% to $2.82. Revenue and earnings beat estimates. For the full year of 2024, […]
· July 17, 2024
Johnson & Johnson (NYSE: JNJ) reported its second quarter 2024 earnings results today.
Reported sales increased 4.3% year-over-year to $22.4 billion. Operational sales growth was 6.6%.
Net income decreased 12.8% to $4.6 billion while EPS dropped 5.9% to $1.93. Adjusted EPS rose 10.2% to $2.82.
Revenue and earnings beat estimates.
For the full year of 2024, JNJ expects reported sales of $88.0-88.4 billion and adjusted EPS of $9.97-10.07.
The stock was down over 1% in premarket hours on Wednesday.
